Post Market Clinical Follow-Up Study on the Performance and Safety of Lyoplant® (LYOPLACE)
Retrospective, Single Center, Single Arm Post Market Clinical Follow-Up (PMCF) Study on the Performance and Safety of Lyoplant® Used for the Replacement and Extension of Connective Tissue Structures in Neurosurgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Diana Kupferschmid
- Phone Number: +49746195
- Email: info@aesculap.de
Study Locations
-
-
Bayern
-
Augsburg, Bayern, Germany, 86156
- Universitätsklinikum Augsburg AöR
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18 years
- Use of investigational device according to Instructions for Use (IfU)
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Lyoplant®
Lyoplant® is a pure collagen implant obtained from bovine pericardium.
The membrane is used for the replacement and extension of connective tissue structures in neurosurgery.
|
replacement and extension of connective tissue structures in neurosurgery
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of Cerebrospinal Fluid Leakage
Time Frame: at one follow-up ≥ 3 months after surgery
|
A Cerebrospinal Fluid (CSF) leakage needs to be confirmed by radiological image evaluation (computed tomography scan, CT or magnetic resonance imaging scan, MRI).
It will be documented if the CSF leak was clinically evident or not.
A clinically evident CSF leak is defined as clear fluid leaking through the surgical incision or orifice (e.g., rhinorrhea or otorrhea) or as subcutaneous visible and / or palpable fluid accumulation next to or at the site of surgical incision suspected to be CSF.
A non-clinically evident CSF leak is defined as CSF accumulation which could be detected only by radiological image evaluation (CT / MRI).
|
at one follow-up ≥ 3 months after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of re-operations with product relationship
Time Frame: at one follow-up ≥ 3 months after surgery
|
e.g.
caused by infection, foreign-body-reaction/ hypersensitivity against proteins of bovine origin/ allergic reactions to proteins of bovine origin
|
at one follow-up ≥ 3 months after surgery
|
|
Incidence of further (serious) adverse events in chronologic sequence
Time Frame: intra- and postoperative, until follow-up ≥ 3 months after surgery
|
Number of further serious adverse events e.g.
meningitis, surgical site infection, inflammation rate, hematoma - with focus on events with (possible) relation to the investigational product.
|
intra- and postoperative, until follow-up ≥ 3 months after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Philipp E Krauss, Dr., Universitätsklinikum Augsburg AöR
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Neoplasms by Site
- Neoplasms
- Nervous System Neoplasms
- Craniocerebral Trauma
- Trauma, Nervous System
- Central Nervous System Neoplasms
- Brain Neoplasms
- Infratentorial Neoplasms
- Brain Injuries
- Cerebellar Diseases
- Brain Injuries, Traumatic
- Cerebellar Neoplasms
- Cerebral Ventricle Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- AAG-O-H-2112
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.